A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
Fehniger TA, Watkins MP, Ezenwajiaku N, Wan F, Hurd DD, Cashen AF, Blum KA, Goy A, Fenske TS, Wagner-Johnston ND, Carson K, Siegel MJ, Russler-Germain D, Schneider SE, Mehta-Shah N, Kahl B, Bartlett NL.
Fehniger TA, et al. Among authors: carson k.
Haematologica. 2024 Mar 1;109(3):953-957. doi: 10.3324/haematol.2022.282246.
Haematologica. 2024.
PMID: 37706336
Free PMC article.
Clinical Trial.
No abstract available.